Our earlier studies of rat brain phospholipase D1 (rPLD1) showed that the enzyme could be activated in cells by α subunits of the heterotrimeric G proteins G 13 and G q . Recently, we showed that rPLD1 is modified by Ser/Thr phosphorylation and palmitoylation. In this study, we first investigated the roles of these post-translational modifications on the activation of rPLD1 by constitutively active G α 13Q226L and G α qQ209L. Mutations of Cys 240 and Cys 241 of rPLD1, which abolish both post-translational modifications, did not affect the ability of either G α 13Q226L or G α qQ209L to activate rPLD1. However, the RhoA-insensitive mutants, rPLD1(K946A, K962A) and rPLD1 (K962Q), were not activated by G α 13Q226L, although these mutant enzymes responded to phorbol ester and G α qQ209L. On the contrary, the PKCinsensitive mutant rPLD1(∆N168), which lacks the first 168 amino acids of rPLD1, responded to G α 13 Q226L but not to G α qQ209L. In addition, we found that rPLD2 was strongly activated by G α qQ209L and phorbol ester. However, surprisingly, the enzymatic activity of rPLD2 was suppressed by G α 13Q226L and constitutively active V 14 RhoA in COS 7 cells. Abolition of the post-translational modifications of rPLD2 did not alter the effects of G α qQ209L or G α 13Q226L. The suppressive effect of G α 13Q226L on rPLD2 was reversed by dominant negative N 19 RhoA and the C3 exoenzyme of C. botulinum, further supporting a role for RhoA. In summary,
PKC. rPLD2 is activated by G α q, but is inhibited by G α 13. Neither Ser/Thr phosphorylation nor palmitoylation is required for these effects.
INTRODUCTION
Phospholipase D (PLD) 1 is a ubiquitous enzyme that hydrolyzes phosphatidylcholine to phosphatidic acid and choline (1) . Phosphatidic acid is generally recognized as the signaling product of PLD action, but it can be converted to diacylglycerol or lysophosphatidic acid.
Although the physiological role of PLD remains unclear, multiple functions have been proposed based on the actions of phosphatidic acid and its derivatives, and the involvement of PLD in signaling pathways (2, 3) .
PLD is highly regulated and responds to many growth factors, hormones and agonists (1, 2) . The responses are mediated by either tyrosine kinase-or heterotrimeric G proteincoupled receptors. For example, epidermal growth factor and platelet-derived growth factor function through receptor tyrosine kinases and require downstream small G proteins and PKC for the stimulation of PLD activity (4, 5) . Receptors linked to heterotrimeric G proteins of the G q and G i families have also been shown to induce PLD activation in many cell types (1, 6) , while G 12/13 proteins have been shown to be involved in PLD stimulation by M3 muscarinic acetylcholine receptors in HEK293 cells (7, 8) .
To date, two isoforms of mammalian PLD (PLD1 and PLD2) have been cloned. These isoforms share about 50% amino acid similarity, but exhibit quite different regulatory properties.
PLD1 has a low basal activity and responds to PKC and members of the Rho, ARF and Ras/Ral families of small G proteins (9) (10) (11) (12) (13) (14) . PLD2, on the other hand, exhibits a high basal activity and shows little or no response to stimuli compared to PLD1 (15-17). However, a recent study has shown that PLD2 can be tyrosine phosphorylated and its activity up-regulated in HEK293 cells treated with epidermal growth factor (18). In addition, exogenously expressed PLD2 in HEK293 cells has been shown to be stimulated by insulin (19) . The precise cellular localization of the two isoforms is not well defined, although PLD1 is generally believed to be located at the perinuclear region, while PLD2 is at plasma membrane (20).
Characterization of PLD1 and PLD2 has defined multiple functional domains and interesting properties of the enzymes. PLD belongs to a superfamily defined by the "HKD" motif HxK(x) 4 D (21-23). PLD contains two copies of the HKD motif located in the N-and Cterminal halves of the molecule and both motifs are required for the enzymatic activity (24-25).
Our studies on rat PLD1 (rPLD1) showed that there is an interdomain association between the N-and C-terminal halves of the molecule and this is important for the catalytic activity (25-26).
Another domain essential for the catalytic activity of PLD is located at the C-terminus of the enzyme, and deletion of the last amino acid of rPLD1 abolishes its enzymatic activity (27) (28) 30 ). Besides the motifs essential for the catalysis, domains important for the PKC and Rho responses have been mapped to the N-terminal and C-terminal regions of the enzyme, respectively (29-32). In addition, recent studies of rPLD1 in COS 7 cells have revealed that the molecule is modified by Ser/Thr phosphorylation (26) and palmitoylation (33-34). These two post-translational modifications are interrelated and require association between the N-and Cterminal halves of rPLD1 and the presence of the N-terminal amino acids of the enzyme (33).
Although neither palmitoylation nor phosphorylation was found to be essential for the catalysis of rPLD1(33), the modifications played roles in specifying the cellular location of the enzyme (34) and strengthening its association with membranes (33). Earlier studies of rPLD1 expressed in COS 7 cells showed that it was stimulated by constitutively active G α 13 and G α q (35). Here we investigated the effects of these activated α-subunits on rPLD1 and rPLD2 and tested whether the Ser/Thr phosphorylation or palmitoylation of the enzymes play roles in the effects. In addition, we used rPLD1 mutants that are unable to respond to PKC or to Rho to dissect the downstream effectors that mediate the effects of G α 13 and G α q.
EXPERIMENTAL PROCEDURES
Materials -4β-Phorbol 12-myristate 13-acetate (PMA), bovine serum albumin, Triton X-100 and microcystin were from Sigma. Phosphatidylbutanol (PtdBut) standard was from Avanti Polar Lipids Corp. (Vanderbilt University) . RhoA, G α q and G α 13 antibodies were from Santa Cruz, and antimouse and anti-rabbit antibodies conjugated with horseradish peroxidase were from Vector Laboratories. C3 exoenzyme from C. botulinum was from Cytoskeleton, Denver CO. The Rho kinase inhibitor Y-27632 was kindly provided by Yoshitomi Pharmaceutical Industries Ltd., Saitama, Japan.
Plasmid Construction -N-terminal Xpress-tagged full length or truncated rPLD1 was created by PCR amplification and subcloned (11) . The rPLD2 clone was obtained by PCR amplification using a rat brain quick cDNA mix (Clontech) and the PCR product was subcloned in frame with the N-terminal Xpress tag in PcDNA3 vector. The deletion or site-directed mutations of rPLD1 were generated as described in the QuickChange TM Site-Directed Mutagenesis Instruction manual from Stratagene. All the constructs were sequenced to verify the coding regions of rPLD1. The PKC-insensitive and RhoA-insensitive rPLD1 mutants, rPLD1 (K946A, K962A) and rPLD1 (K962Q) were generated as described (25,32). Constitutive active G α 13 Q226L and G α qQ209L were generated as described (35).
Cell Culture and Transfection -COS-7 cells were maintained in DMEM supplemented with 4 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin and 10% FBS in humidified 10% CO 2 . Six-well plates were seeded with 2 x 10 5 COS 7 cells per well and 10 cm-dishes were seeded with 6 x 10 5 cells and transfected with FuGENE6 according to the manufacturer's instructions.
In vivo PLD Assay -After 6 h transfection with FuGENE6, COS 7 cells in 6-well plates were serum-starved (0.5% FBS in DMEM) in the presence of 1 µCi/ml [ 3 H]myristic acid. After overnight starvation, the cells were washed with phosphate-buffered saline (PBS) and incubated in serum-free medium supplemented with 0.3% bovine serum albumin for 50 min. PLD activity was then assayed as described (25). Briefly, cells were incubated in 0.3% 1-butanol for 25 min.
Cells were then washed with ice-cold PBS and stopped with methanol. Lipids were extracted, and the PtdBut product was resolved by thin layer chromatography. Bands co-migrating with a PtdBut standard were quantitated by scintillation counting. The results are as the percentage of total lipid radioactivity that is incorporated into PtdBut.
Western Blotting -Protein samples were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 8% gels and transferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore). The blots were then blocked with 5% non-fat milk and incubated with appropriate primary antibodies followed by incubation with horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands were detected using enhanced chemiluminescence.
Scrape Loading with C3 Exoenzyme -After 6 h transfection, cells growing on 100 mm dishes were washed with 5 ml of PBS and then with 2 ml of scraping buffer (114 mM KC1, 15 mM NaCl, 5.5 mM MgCl 2 , 10 mM Tris-HC1). Cells were gently scraped in 0.5 ml of scraping buffer containing 0 or 5 mg/ml C3 exoenzyme. After brief centrifugation, cells were resuspended in DMEM containing 10% fetal bovine serum and split into 6-well plates.
Following 24 h of culture, the scrape-loaded cells were serum-starved and labeled with In the present study, we used several rPLD1 mutants that have specifically lost responses to PKC or Rho to dissect the downstream effectors that mediate the activation of rPLD1 by G α 13 and G α q. rPLD1(∆N168), which lacks the first 168 amino acids, does not respond to PKC but is able to respond to Rho activation (29). On the other hand, certain site-directed rPLD1 mutants, namely rPLD1(K946A, K962A) and rPLD1(K962Q), are insensitive to Rho stimulation, but can be activated by PKC (32).
We first examined the effects of constitutively active G α 13Q226L on wild type rPLD1 and mutant rPLD1s that are unresponsive to Rho activation. These rPLD1 constructs were either transfected alone or cotransfected with G α 13Q226L into COS 7 cells and in vivo PLD activity was measured. As shown in Fig. 1A , wild type rPLD1 was effectively activated by G α 13Q226L. However, rPLD1(K946A, K962A) and rPLD1(K962Q), which are unresponsive to Rho (32), were not stimulated by G α 13Q226L. These mutants were well expressed in comparison to wild-type rPLD1 (Fig.1B) . Although they showed lower basal activity ( Fig. 1A and 1C ), they responded fully to PMA stimulation ( Fig. 1C and Ref. 32). Furthermore, when these Rhoinsensitive mutants were examined for their response to co-transfected constitutively active G α qQ209L, they all responded strongly (data not shown). In agreement with previous findings (35), G α 13Q226L had no effect on the endogenous PLD of COS 7 cells (data not shown).
We next examined the effects of G α 13Q226L and G α qQ209L on rPLD1(∆N168). This N-terminal deletion mutant of rPLD1 does not respond to PMA (PKC) stimulation, but retains the ability to respond to RhoA (29). As shown in Fig. 2A , although this mutant had higher basal activity than wild type enzyme (25,29), it was further stimulated when cotransfected with G α 13Q226L in COS 7 cells. The higher activity of rPLD1(∆N168) and its enhanced response to G α 13Q226L could not be attributed to increased expression (Fig. 2B ). Constitutively active G α qQ209L had a small effect on endogenous PLD and markedly stimulated wild type rPLD1 (Fig.   3A ), but unmutated G α q was ineffective (data not shown). However, minimal stimulation was observed when rPLD1(∆N168) was cotransfected with G α qQ209L (Fig. 3A) . The rPLD1(∆N168) constructs were expressed to a similar extent (Fig. 3B ). The stimulation of wild type rPLD1 by G α qQ209L was non-additive with that induced by PMA (data not shown), consistent with their mediation by PKC.
In summary, the foregoing results showed that rPLD1 activation by G α 13 was dependent on the interaction of the enzyme with the small G protein Rho, while activation by G α q did not require this. However, the N-terminal 168 amino acids which contain a PKC interaction site(s)
were required for the activation of rPLD1 by G α q, but not G α 13.
Neither Ser/Thr Phosphorylation nor Palmitoylation of rPLD1 is Required for G α 13 or G α q Activation -Recent studies of PLD1 have shown that the enzyme can be modified by Ser/Thr phosphorylation and palmitoylation. Although neither modification was essential for catalysis (26,33), they played roles in specifying the cellular location of the enzyme (34) and strengthening its association with membranes (26,33). We thus examined whether these posttranslational modifications played specific roles in the activation of rPLD1 by G α 13 or G α q.
We utilized the double cysteine mutant, rPLD1(C241A, C242A), which lacks palmitoylation and phosphorylation. Our previous study showed that this mutant retained the ability to respond to PKC activation in vivo (33). The mutant rPLD1was transfected alone or cotransfected with G α 13Q226L or G α qQ209L and the PLD activity measured. As shown in Fig. 4A , rPLD1(C241A, C242A) had dramatically reduced activity as compared with wild type enzyme, but the enzyme was well expressed (Fig. 4B ) and responded to PMA stimulation (33 and data not shown).
When cotransfected with G α 13Q226L or G α qQ209L, the double cysteine mutant responded markedly to stimulation by both α-subunits ( Fig. 4A and 5A) . Indeed, the fold response of rPLD1(C241A, C242A) to G α 13Q226L or G α qQ209L was greater than wild type enzyme. Both rPLD1 and rPLD1 (C241A, C242A) were expressed at comparable levels when transfected alone or cotransfected with the G protein α-subunits (Fig. 4B and 5B). Thus, neither Ser/Thr phosphorylation nor palmitoylation of rPLD1 is required for the activation of the enzyme by G α 13 or G α q.
rPLD2 is Activated by G α q and Phorbol Ester, but is Suppressed by G α 13 -PLD2 has quite different properties from PLD1 (15-19). PLD2 has a high basal activity and shows no responses to PKC, ARF and RhoA in vitro and modest responses to PKC and Arf in vivo (16,17). We next investigated the response of rPLD2 to constitutively active G α 13 and G α q in COS 7 cells. As shown in Fig. 6A , 6B, 7A and 7B, both rPLD1 and rPLD2 were well expressed and showed large responses to G α qQ209L. When the amount of plasmid DNA transfected was varied, rPLD2 was consistently expressed to a greater extent than rPLD1 and showed a higher basal activity (Fig. 7A, 7B and data not shown). As previously noted (26, 33), rPLD1 showed an upper phosphorylated band on SDS-PAGE whereas rPLD2 migrated as a single band ( Fig. 6B and 7B). Unexpectedly, co-expression of constitutively active G α q enhanced the appearance of the lower band of rPLD1 ( Fig. 6B and 7B ), but we did not explore the basis for this. Both isozymes showed large responses to PMA, but there was little difference between the isozymes in the total activity observed in the presence of the phorbol ester (Fig. 7A ). The increases with PMA were much greater than those observed with G α q209L. Possible reasons for this are described in the Discussion.
A surprising observation was that, whereas rPLD1 was stimulated by G α 13Q226L (Figs. 1A, 2A and 4A), the activity of rPLD2 was suppressed when it was cotransfected with G α 13Q226L (Fig. 8A and subsequent figures) . The suppression of rPLD2 by G α 13Q226L was not due to lack of expression of the enzyme (Fig. 8B) . A palmitoylation-deficient mutant of rPLD2
showed much loss of basal activity, but responded well to G α q209L (Fig. 8A) . The activity of the mutant rPLD2 was also suppressed by G α 13Q226L, although the effect was not large due to its already low activity.
Role of RhoA in the Suppression of rPLD2 by G α 13 -In view of the evidence that G α 12/13 effects are mediated by RhoA ( Fig. 1 and Refs 35-42), we tested to see if this small G protein was involved in the suppression of rPLD2 activity by G α 13Q226L. Figure 9A shows the effects of dominant negative N 19 RhoA on the action of G α 13Q226L. This RhoA mutant produced a small increase in rPLD2 activity, but more importantly, reversed the inhibition of PLD activity caused by G α 13Q226L. Dominant negative Rac1 was also tested, but had minimal effects (data not shown). To obtain further evidence for a role of RhoA, constitutively active V 14 RhoA was also tested, and this form of RhoA suppressed rPLD2 activity significantly (Fig.   10A ). Figures 9B and 10B show that rPLD2, G α 13Q226L and RhoA were all well-expressed.
The C3 exoenzyme of Clostridium botulinum inactivates Rho proteins through ADPribosylation (36). This toxin reversed the inhibitory effect of G α 13Q226L on rPLD2 (Fig. 11A) and also abolished the effect of V 14 RhoA (data not shown). It had no effects on the expression of either rPLD2 or G α 13Q226L (Fig. 11B) . To explore the possible role of Rho kinase in the actions of G α 13Q226L or RhoA on rPLD1 and rPLD2, we tested the effects of the Rho kinase 40,43,44) . However, although G α q has the potential to activate Rho, this did not lead to activation of rPLD1 in COS 7 cells (Fig. 3) . As shown in this figure, rPLD1(∆N168), which does not respond to PKC but retains the ability to respond to Rho, was not activated by G α q. Furthermore, studies of human PLD2 have shown that the enzyme is activated by insulin treatment in HEK293 cells, and this activation is mediated by PLC and PKC (19). G α q is well known to activate PLC which, in turn, leads to activation of PKC, and the data of Fig. 3 with Nterminally truncated rPLD1 support the idea that the activation of rPLD1 by G α q is mediated by PKC. As expected from previous studies (11, 12, 25, 26) , PMA increased rPLD1 activity in COS 7 cells (Fig. 7A ), but the increase was much larger than that observed with G α qQ209L. This presumably reflects the greater ability of the phorbol ester to activate PKC compared with diacylglycerol generated endogenously through the activation of PLC. Another possibility is that transfection of the cells for 24 h with constitutively active G α q may have led to down-regulation of PKC.
DISCUSSION
PMA activated rPLD2 to approximately the same extent as rPLD1 (Fig. 7A) . This was surprising in view of in vitro observations (12) and was not attributable to differences in the expression of the PLD isozymes (Fig. 7B) . Although several groups have demonstrated that PLD1 can be activated by conventional isozymes of PKC through a non-phosphorylating mechanism in vitro (10,46-50), it is possible that a different mechanism involving phosphorylation is utilized by PKC in vivo. Whether or not the PLD isozymes themselves or other interacting proteins are phosphorylated remains to be defined. Direct phosphorylation of PLD1 by PKCα in vitro does not result in activation (10,49). However, there have been reports indicating that PLD1 is phosphorylated and activated by PKC in vivo (51,52). Our studies indicate that neither palmitoylation nor the associated phosphorylation of either rPLD1 or rPLD2 significantly modify its response to G α q in COS 7 cells (Fig. 5 and 8) . Previous work has shown that these post-translational modifications do not impair the response of either isozyme to PMA (33,53).
It was surprising and interesting to find that rPLD2 activity was suppressed when cotransfected with G α 13Q226L (Fig. 7-10 ). This was in marked contrast to rPLD1, which was activated. rPLD2 differs from rPLD1 is that it is not extensively modified by Ser/Thr phosphorylation, although it is palmitoylated (53). However, in this study we found that both these post-translational modifications of rPLD1 or rPLD2 were not required for the effects of either G α q or G α 13. Thus, lack of Ser/Thr phosphorylation is unlikely to be responsible for the different response of rPLD2 to the activation of G α 13.
Human PLD2 shows no change in catalytic activity when assayed in vitro in the presence of RhoA-GTPγS (16). Due to its high basal activity, any inhibitory effect of Rho should have been discernible. However, it is suppressed by constitutively active V 14 RhoA when assayed in COS 7 cells, and the inhibitory effect of active G α 13 is reversed by dominant negative N 19 RhoA. These findings indicate that Rho mediates the inhibition by G α 13. We were unable to implicate Rho kinase in the effects of V 14 RhoA or G α 13 on either rPLD1 or rPLD2. Although an inhibitor of Rho kinase (Y-27632) reduced their stimulatory effects on rPLD1, a similar magnitude of inhibition was observed when the inhibitor was tested against PMA, indicating a lack of specificity in this system. With respect to the effects of the inhibitor on rPLD2, no consistent changes were observed.
As discussed above for PLD1, the in vivo effects of PKC on PLD2 could involve another protein(s) and this is also true for the action of RhoA on this isozyme. PLD2 has a much higher basal activity than PLD1 in vitro, but this difference is less evident in vivo (Fig. 6A and 7A and 
Ref. 16 and 45). This may be because there is suppression of PLD2 activity in intact cells (16).
Several inhibitors of PLD2 have been reported. These include (α-and β-synucleins (54), α-actinin (55), β-actin (56) amphiphysins (57) and also proteins that reduce the cellular level of phosphatidylinositol 4,5-P 2 (60,61). However, most of these proteins also act on PLD1 and are therefore unlikely to specifically suppress PLD2 or mediate a selective inhibitory effect of RhoA on this isozyme. RhoA has many cellular targets (36,60) but their possible links to PLD2 are presently unknown. Thus the intriguing observation that G α 13 and RhoA have opposite effects on PLD1 and PLD2 in vivo requires much further work to elucidate the mechanisms and functional significance. Wild type or N-terminally truncated mutant rPLD1(∆N168), was either transfected alone or cotransfected with constitutively active G α 13Q226L into COS 7 cells as indicated in the figure.
A, PLD activity was measured as described in Fig. 1 Wild type or palmitoylation-deficient mutant rPLD1(C241A, C242A) was either transfected alone or cotransfected with constitutively active G α qQ209L into COS 7 cells as indicated in the figure.
A, PLD activity was measured as described in Fig. 1 
